Colon Cancer Patients on GLP-1s Were Half as Likely to Die Within 5 Years

A UC San Diego study of 6,800+ colon cancer patients found that those taking GLP-1 medications had a 5-year mortality rate of 15.5% compared to 37.1% for non-users. The difference was striking.

The relationship between GLP-1 medications and cancer is one of the most actively studied questions in medicine right now. And while the jury is still out on whether these drugs prevent cancer from developing, a UC San Diego study published in Cancer Investigation provided one of the most dramatic data points yet — this time on survival. UC San Diego

The Study

Researchers led by Raphael Cuomo, Ph.D., at UC San Diego School of Medicine analyzed real-world clinical data from the University of California Health Data Warehouse — covering all UC Health academic medical centers across California. The study included more than 6,800 colon cancer patients.

After comparing outcomes between patients who were taking GLP-1 medications (for diabetes or weight management) and those who were not, the difference in five-year mortality was stark: 15.5% in the GLP-1 group versus 37.1% in the non-GLP-1 group.

Why This Might Be Happening

Researchers have identified several potential mechanisms that could explain improved cancer outcomes in GLP-1 users:

Reduced obesity-driven inflammation. Chronic low-grade inflammation associated with obesity is a known promoter of cancer growth and progression. GLP-1 medications reduce inflammatory markers directly, potentially creating a less hospitable environment for tumor growth.

Improved metabolic health. Better insulin sensitivity, lower blood glucose, and reduced insulin levels may all contribute. Insulin and insulin-like growth factors (IGF) can promote cancer cell growth, and reducing their levels may slow tumor progression.

Direct anti-tumor effects. Emerging laboratory research from Duke Cancer Institute has shown that GLP-1 medications can restore cancer-fighting immune function that obesity had suppressed. In animal models, GLP-1-treated mice developed tumors more slowly — even while still on a high-fat diet. Duke Med

Important Caveats

This was a retrospective observational study, and there are significant limitations. Patients on GLP-1 medications may differ from non-users in ways that affect cancer outcomes — they may have better overall healthcare access, be more health-conscious, or have different comorbidity profiles. The study adjusted for some of these factors, but unmeasured confounders likely exist.

Additionally, a separate large analysis published in the Annals of Internal Medicine found that GLP-1 medications had "little or no effect" on the risk of developing 13 obesity-related cancers. So the evidence for cancer prevention is still uncertain — but the survival data in patients who already have cancer is genuinely compelling.

Ready to Get Started?

These verified telehealth providers offer GLP-1 programs with medical oversight and home delivery:

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content or provider selection.